An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

NCT02589717 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: Atezolizumab [TECENTRIQ]

Sponsor

Genentech, Inc.